---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-062031"
form_type: "8-K"
ticker: "TRVI"
cik: "0001563880"
company_name: "Trevi Therapeutics, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:41:15.616418+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Trevi Therapeutics Q3 2023 net loss $7.7M; initiates Phase 2a RIVER trial for Haduvio in RCC

## Summary
- Net loss $7.7M in Q3 2023 vs $8.3M in Q3 2022; cash, equivalents $88.9M.
- Initiated Phase 2a RIVER trial of Haduvio in refractory chronic cough; topline data expected H2 2024.
- Plan to initiate Phase 2b dose-ranging trial for chronic cough in IPF in Q4 2023; Phase 1b trial in Q1 2024.
- Open-label extension of PRISM trial in prurigo nodularis showed sustained itch reduction and safety over 52 weeks.
- R&D expenses $6.3M, G&A $2.7M; other income $1.3M due to higher interest income.

## SEC filing metadata
- accession: 0000950170-23-062031
- form_type: 8-K
- ticker: TRVI
- cik: 0001563880
- company_name: Trevi Therapeutics, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000095017023062031/0000950170-23-062031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000095017023062031/trvi-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-062031
- JSON: https://secwatch.observer/filing/0000950170-23-062031.json
- Plain text: https://secwatch.observer/filing/0000950170-23-062031.txt

## Key facts
- Earnings Releases
  Trevi Therapeutics, Inc. reported quarter ended September 30, 2023 results: net income net loss of $7.7 million.
  - Period: quarter ended September 30, 2023
  - Net income: net loss of $7.7 million
  - Result: reported results
  source text: For the third quarter of 2023, the Company reported a net loss of $7.7 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1563880/000095017023062031/0000950170-23-062031-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.